AD-2646

• Description:

  AD-2646 (LCL102), a ceramide analog, can kill leukemic T cells (EC50: 40 μM) . AD-2646 triggers the cleavage of caspase-8, -9 and -3, as well as the caspase substrate PARP. AD-2646 is a ceramidase inhibitor. AD-2646 induces an accumulation of endogenous ceramide owing to perturbed ceramide metabolism[1][2].

• Product Name Alternative:

  LCL102

• UNSPSC:

  12352005

• Target:

  Caspase; Ceramidase; PARP

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ad-2646.html

• Smiles:

  O[C@H] (C1=CC=C ([N+] ([O-]) =O) C=C1) [C@H] (NCCCCCCCCCCCCCC) CO

• Molecular Formula:

  C23H40N2O4

• Molecular Weight:

  408.57

• References & Citations:

  [1]Granot T, et al. Caspase-dependent and -independent cell death of Jurkat human leukemia cells induced by novel synthetic ceramide analogs. Leukemia. 2006 Mar;20 (3) :392-9.|[2]Fumiaki Tanaka, et al. In Vivo and In Vitro Inhibition of Human Cancer Cell Growth Using Adenoviral Vector Expressing FHIT Gene: Mechanism Analysis Using Microarray. Volume 7, Issue 5, Supplement S418-S419. May 2003.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  Caspase 3; Caspase 8; Caspase 9

• CAS Number:

  366487-89-0